EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy for lung cancer shows promise in safety trial
Disease control OngoingThis study looks at whether it is safe to continue the targeted cancer drug osimertinib while also giving radiation therapy to people with advanced EGFR-positive non-small cell lung cancer. The goal is to control tumors that start growing again during treatment. About 42 adults a…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated May 26, 2026 04:41 UTC
-
New hope for drug-resistant lung cancer? early trial combines two targeted therapies
Disease control OngoingThis early-stage study tests a new drug (APG-1252) combined with a standard targeted therapy (osimertinib) in people with a specific type of advanced lung cancer (EGFR-positive NSCLC) whose cancer has stopped responding to previous treatments. The main goals are to find the safes…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC